Cutaneous lymphomas: Molecular pathways leading to new drugs

Journal of Investigative Dermatology

Volumn 132, Issue 3 PART 1, 2012, Pages 517-525

  Dummer, Reinhard ^a   Goldinger, Simone M ^a   Cozzio, Antonio ^a   French, Lars E ^a   Karpova, Maria B ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BELINOSTAT; BORTEZOMIB; DACINOSTAT; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RITUXIMAB; ROMIDEPSIN; VALPROATE SEMISODIUM; VORINOSTAT;

CELL CYCLE REGULATION; CELL HETEROGENEITY; CUTANEOUS B CELL LYMPHOMA; CUTANEOUS T CELL LYMPHOMA; EPIGENETICS; HISTONE ACETYLATION; HUMAN; LYMPHOCYTE; METHYLATION; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SKIN LYMPHOMA; TREATMENT OUTCOME;

EID: 84857039428     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.370     Document Type: Note

References (119)

1. Akilov OE, Geskin L (2011) Therapeutic advances in cutaneous T-cell lymphoma. Skin Therapy Lett 16:1-5
2. Amoroso A, Hafsi S, Militello L et al. (2011) Understanding rituximab function and resistance: Implications for tailored therapy. Front Biosci 16:770-82
3. Ansell SM, Horwitz SM, Engert A et al. (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 25:2764-9 (Pubitemid 47123185)
4. Ballabio E, Mitchell T, van Kester MS et al. (2010) MicroRNA expression in Sezary syndrome: Identification, function, and diagnostic potential. Blood 116:1105-13
5. Bensussan A, Remtoula N, Sivori S et al. (2011) Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sezary syndrome patients. J Invest Dermatol 131:969-76
6. Bernengo MG, Quaglino P, Comessatti A et al. (2007) Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: Clinical and immunologic findings in 14 patients. Haematologica 92:784-94 (Pubitemid 350155304)
7. Brody JD, Ai WZ, Czerwinski DK et al. (2010) In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: A phase I/II study. J Clin Oncol 28:4324-32
8. Brogdon JL, Xu Y, Szabo SJ et al. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109:1123-30 (Pubitemid 46220659)
9. Burg G, Kempf W, Cozzio A et al. (2005) WHO/ EORTC classification of cutaneous lymphomas 2005: Histological and molecular aspects. J Cutan Pathol 32:647-74 (Pubitemid 41719746)
10. Campbell JJ, Clark RA, Watanabe R et al. (2010) Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: A biologic rationale for their distinct clinical behaviors. Blood 116:767-71
11. Cao Y (2005) Opinion: Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 5:735-43 (Pubitemid 41486366)
12. Carter CA, Kelly RJ, Giaccone G (2009) Smallmolecule inhibitors of the human epidermal receptor family. Expert Opin Investig Drugs 18:1829-42
13. Chauhan D, Hideshima T, Mitsiades C et al. (2005) Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 4:686-92 (Pubitemid 40601851)
14. Clark RA, Shackelton JB, Watanabe R et al. (2011) High-scatter T cells: A reliable biomarker for malignant T cells in cutaneous T-cell lymphoma. Blood 117:1966-76
15. Dhillon AS, Hagan S, Rath O et al. (2007) MAP kinase signalling pathways in cancer. Oncogene 26:3279-90 (Pubitemid 46763021)
16. Dummer R, Eichmuller S, Gellrich S et al. (2010) Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol Ther 18:1244-7
17. Dummer R, Hassel JC, Fellenberg F et al. (2004) Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 104:1631-8 (Pubitemid 39202268)
18. Dummer R, Heald PW, Nestle FO et al. (1996) Sezary syndrome T-cell clones display Thelper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor betachain). Blood 88:1383-9 (Pubitemid 26276814)
19. Dummer R, Kohl O, Gillessen J et al. (1993) Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. Arch Dermatol 129:433-6 (Pubitemid 23118238)
20. Dummer R, Urosevic M, Kempf W et al. (2003) Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology 207:116-8
21. Duvic M, Talpur R, Ni X et al. (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-9 (Pubitemid 46053039)
22. Ellis L, Pan Y, Smyth GK et al. (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous Tcell lymphoma. Clin Cancer Res 14:4500-10
23. Eriksen KW, Kaltoft K, Mikkelsen G et al. (2001) Constitutive STAT3-activation in Sezary syndrome: Tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 15:787-93 (Pubitemid 32492702)
24. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10:223-32
25. Foss FM, Zinzani PL, Vose JM et al. (2011) Peripheral T-cell lymphoma. Blood 117:6756-67
26. Garcia-Manero G (2008) Demethylating agents in myeloid malignancies. Curr Opin Oncol 20:705-10
27. Gimsing P (2009) Belinostat: A new broad acting antineoplastic histone deacetylase inhibitor. Expert Opin Investig Drugs 18:501-8
28. Gorre ME, Mohammed M, Ellwood K et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (New York, NY) 293:876-80 (Pubitemid 32743979)
29. Hacker S, Dittrich A, Mohr A et al. (2009) Histone deacetylase inhibitors cooperate with IFNgamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 28:3097-110
30. Hahtola S, Tuomela S, Elo L et al. (2006) Th1 response and cytotoxicity genes are downregulated in cutaneous T-cell lymphoma. Clin Cancer Res 12:4812-21 (Pubitemid 44338565)
31. Hamamura RS, Ohyashiki JH, Kurashina R et al. (2007) Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells. Br J Cancer 97:1099-105 (Pubitemid 47587016)
32. Heider U, Rademacher J, Lamottke B et al. (2009) Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur J Haematol 82:440-9
33. Heinrich MC, Corless CL, Demetri GD et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-9 (Pubitemid 46621810)
34. Hennessy BT, Hanrahan EO, Daly PA (2004) Non-Hodgkin lymphoma: An update. Lancet Oncol 5:341-53 (Pubitemid 38691037)
35. Hoebe K, Janssen E, Beutler B (2004) The interface between innate and adaptive immunity. Nat Immunol 5:971-4 (Pubitemid 41057712)
36. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA et al. (2006) Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 24:1612-9 (Pubitemid 46638785)
37. Jazirehi AR, Bonavida B (2005) Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention. Oncogene 24:2121-43 (Pubitemid 40516580)
38. Kamstrup MR, Gjerdrum LM, Biskup E et al. (2010) Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood 116:2504-12
39. Kantarjian H, Oki Y, Garcia-Manero G et al. (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higherrisk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-7 (Pubitemid 46053042)
40. Karpova MB, Fujii K, Jenni D et al. (2010) Evaluation of lymphangiogenic markers in Sezary syndrome. Leuk Lymphoma 52:491-501
41. Kasprzycka M, Zhang Q, Witkiewicz A et al. (2008) Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunol 181:2506-12
42. Kempf W, Sander CA (2010) Classification of cutaneous lymphomas-an update. Histopathology 56:57-70
43. Kennah E, Ringrose A, Zhou LL et al. (2009) Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells. Blood 113:4646-55
44. Kerl H, Cerroni L (2006) Primary cutaneous B-cell lymphomas: Then and now. J Cutan Pathol 33(Suppl 1):1-5
45. Khan O, Fotheringham S, Wood V et al. (2010) HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci USA 107:6532-7
46. Kiessling MK, Klemke CD, Kaminski MM et al. (2009) Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species-and iron-dependent cell death in cutaneous T-cell lymphoma. Cancer Res 69:2365-74
47. Kiessling MK, Oberholzer PA, Mondal C et al. (2011) High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood 117:2433-40
48. Kim YH, Duvic M, Obitz E et al. (2007) Clinical efficacy of zanolimumab (HuMax-CD4): Two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109:4655-62 (Pubitemid 46827755)
49. Kim YH, Girardi M, Duvic M et al. (2010) Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment- refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 63:975-83
50. Krejsgaard T, Gjerdrum LM, Ralfkiaer E et al. (2008) Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome. Leukemia 22:2230-9
51. Krejsgaard T, Ralfkiaer U, Clasen-Linde E et al. (2011) Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol 131:1331-8
52. Krejsgaard T, Vetter-Kauczok CS, Woetmann A et al. (2006) Jak3-and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 20:1759-66 (Pubitemid 44574987)
53. Krejsgaard T, Vetter-Kauczok CS, Woetmann A et al. (2009) Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma. Blood 113:5896-904
54. Kremer M, Sliva K, Klemke CD et al. (2010) Cutaneous T-cell lymphoma cells are sensitive to rapamycin. Exp Dermatol 19:800-5
55. Kuppers R (2005) Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5:251-62 (Pubitemid 40488631)
56. Lacrima K, Valentini A, Lambertini C et al. (2005) In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 16:1169-76 (Pubitemid 41418321)
57. Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547-66
58. Leonard JP, Furman RR, Coleman M (2006) Proteasome inhibition with bortezomib: A new therapeutic strategy for non-Hodgkin's lymphoma. Int J Cancer 119:971-9 (Pubitemid 44121415)
59. Lohela M, Bry M, Tammela T et al. (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21:154-65
60. Mandriota SJ, Jussila L, Jeltsch M et al. (2001) Vascular endothelial growth factor-Cmediated lymphangiogenesis promotes tumour metastasis. EMBO J 20:672-82 (Pubitemid 32167632)
61. Manfe V, Holst LM, Rosbjerg A et al. (2010) Changes in oncomiR expression in CTCL cell lines during apoptosis induced by Notch inhibition. Leuk Res 34:e235-6
62. Mann BS, Johnson JR, Cohen MH et al. (2007) FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12:1247-52 (Pubitemid 350106355)
63. Marks PA, Richon VM, Miller T et al. (2004) Histone deacetylase inhibitors. Adv Cancer Res 91:137-68 (Pubitemid 39140958)
64. Marks PA, Xu WS (2009) Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107:600-8
65. Martin GS (2003) Cell signaling and cancer. Cancer cell 4:167-74 (Pubitemid 37163830)
66. Martin SJ, Duvic M (2011) Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clin Lymphoma Myeloma Leuk 11:286-8
67. Mazur G, Wozniak Z, Wrobel T et al. (2004) Increased angiogenesis in cutaneous T-cell lymphomas. Pathol Oncol Res 10:34-6 (Pubitemid 38506610)
68. McKenzie RC, Jones CL, Tosi I et al. (2011) Constitutive activation of STAT3 in Sezary syndrome is independent of SHP-1. Leukemia; e-pub ahead of print 5 August 2011
69. Medzhitov R, Janeway C Jr (2000) The Toll receptor family and microbial recognition. Trends Microbiol 8:452-6
70. Mitchell TJ, Whittaker SJ, John S (2003) Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary Syndrome. Cancer Res 63:9048-54 (Pubitemid 38064087)
71. Mumprecht V, Detmar M (2009) Lymphangiogenesis and cancer metastasis. J Cell Mol Med 13:1405-16
72. Narducci MG, Arcelli D, Picchio MC et al. (2011) MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death Dis 2:e151
73. Navas IC, Algara P, Mateo M et al. (2002) p16(INK4a) is selectively silenced in the tumoral progression of mycosis fungoides. Lab Invest 82:123-32 (Pubitemid 34160450)
74. Nihal M, Stutz N, Schmit T et al. (2011) Polo-like kinase 1 (Plk1) is expressed by cutaneous Tcell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis. Cell Cycle 10:1303-11
75. Oflazoglu E, Kissler KM, Sievers EL et al. (2008) Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 142:69-73 (Pubitemid 351783148)
76. Olsen E, Vonderheid E, Pimpinelli N et al. (2007a) Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:1713-22 (Pubitemid 47443880)
77. Olsen EA, Kim YH, Kuzel TM et al. (2007b) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109-15 (Pubitemid 47218059)
78. Olsen EA, Rook AH, Zic J et al. (2011) Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64:352-404
79. Piekarz RL, Frye R, Turner M et al. (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27:5410-7
80. Prince HM, Bishton MJ, Harrison SJ (2009a) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:3958-69
81. Prince HM, Bishton MJ, Johnstone RW (2009b) Panobinostat (LBH589): A potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 5:601-12
82. Prince HM, Whittaker S, Hoppe RT (2009c) How I treat mycosis fungoides and Sezary syndrome. Blood 114:4337-53
83. Querfeld C, Mehta N, Rosen ST et al. (2009) Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: A single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma 50: 1969-76
84. Querfeld C, Rizvi MA, Kuzel TM et al. (2006) The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 126:1641-7
85. Querfeld C, Rosen ST, Guitart J et al. (2011) Multicenter phase II trial of temozolomide in mycosis fungoides/Sezary syndrome: Correlation with O6-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res 17:5748-54
86. Ralfkiaer U, Hagedorn PH, Bangsgaard N et al. (2011) Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood; e-pub ahead of print 24 August 2011
87. Rovedo MA, Krett NL, Rosen ST (2011) Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin. J Invest Dermatol 131:1442-9
88. Samimi S, Benoit B, Evans K et al. (2010) Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: Implications for immune suppression. Arch Dermatol 146:1382-8
89. Scarisbrick JJ, Woolford AJ, Calonje E et al. (2002) Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome. J Invest Dermatol 118:493-9 (Pubitemid 34227167)
90. Schaerer L, Schmid MH, Mueller B et al. (2000) Angiogenesis in cutaneous lymphoproliferative disorders: Microvessel density discriminates between cutaneous B-cell lymphomas and B-cell pseudolymphomas. Am J Dermatopathol 22:140-3 (Pubitemid 30185836)
91. Silverman LR, McKenzie DR, Peterson BL et al. (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895-903 (Pubitemid 46630737)
92. Skobe M, Hawighorst T, Jackson DG et al. (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192-8 (Pubitemid 32148486)
93. Sleijfer S, Ray-Coquard I, Papai Z et al. (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27:3126-32
94. Sors A, Jean-Louis F, Begue E et al. (2008) Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents. Clin Cancer Res 14:901-11 (Pubitemid 351231175)
95. Sors A, Jean-Louis F, Pellet C et al. (2006) Downregulating constitutive activation of the NFkappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 107:2354-63 (Pubitemid 43345555)
96. Strauss SJ, Maharaj L, Hoare S et al. (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 24:2105-12 (Pubitemid 46622122)
97. Stutz N, Nihal M, Wood GS (2011) Pololike kinase 1 (Plk1) in cutaneous T-cell lymphoma. Br J Dermatol 164:814-21
98. Suchin KR, Junkins-Hopkins JM, Rook AH (2002) Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier Imiquimod. Arch Dermatol 138:1137-9 (Pubitemid 35025683)
99. Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513-609 (Pubitemid 28034534)
100. Urosevic M, Dummer R, Conrad C et al. (2005) Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 97:1143-53 (Pubitemid 41511214)
101. Urosevic M, Fujii K, Calmels B et al. (2007) Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas. J Clin Invest 117: 2834-46 (Pubitemid 47529614)
102. Vacca A, Moretti S, Ribatti D et al. (1997) Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer 33:1685-92 (Pubitemid 28123494)
103. van der Fits L, Out-Luiting JJ, van Leeuwen MA et al. (2011a) Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sézary syndrome. J Invest Dermatol; e-pub ahead of print 22 September 2011
104. van der Fits L, van Kester MS, Qin Y et al. (2011b) MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sezary syndrome. J Invest Dermatol 131:762-8
105. van Doorn R, Zoutman WH, Dijkman R et al. (2005) Epigenetic profiling of cutaneous Tcell lymphoma: Promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 23:3886-96 (Pubitemid 46218691)
106. van Kester MS, Ballabio E, Benner MF et al. (2011) miRNA expression profiling of mycosis fungoides. Mol Oncol 5:273-80
107. van Kester MS, Out-Luiting JJ, von dem Borne PA et al. (2008) Cucurbitacin I inhibits Stat3 and induces apoptosis in Sezary cells. J Invest Dermatol 128:1691-5 (Pubitemid 351847375)
108. Vermeer MH, van Doorn R, Dijkman R et al. (2008) Novel and highly recurrent chromosomal alterations in Sezary syndrome. Cancer Res 68:2689-98 (Pubitemid 351556266)
109. Vonderheid E, Bernengo M, Burg G et al. (2002) Update on erythrodermic cutaneous T-cell lymphoma: Report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46:95-106 (Pubitemid 34073484)
110. Willemze R, Jaffe ES, Burg G et al. (2005) WHOEORTC classification for cutaneous lymphomas. Blood 105:3768-85
111. Witt O, Deubzer HE, Milde T et al. (2009) HDAC family: What are the cancer relevant targets? Cancer Lett 277:8-21
112. Wong HK, Mishra A, Hake T et al. (2011) Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 155:150-66
113. Wozniak MB, Villuendas R, Bischoff JR et al. (2010) Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica 95:613-21
114. Wu J, Siddiqui J, Nihal M et al. (2010) Structural alterations of the FAS gene in cutaneous Tcell lymphoma (CTCL). Arch Biochem Biophys 508:185-91
115. Yamamoto K, Utsunomiya A, Tobinai K et al. (2010) Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemialymphoma and peripheral T-cell lymphoma. J Clin Oncol 28:1591-8
116. Younes A, Bartlett NL, Leonard JP et al. (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-21
117. Zhang C, Li B, Zhang X et al. (2010) Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: Potential role for STAT-3 and NF-kappaB signaling. J Invest Dermatol 130: 2110-9
118. Zhang Q, Nowak I, Vonderheid EC et al. (1996) Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 93: 9148-53
119. Zinzani PL, Musuraca G, Tani M et al. (2007) Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 25:4293-7 (Pubitemid 47548570)